To identify oncogenic mechanisms of CARMA1-activating mutations, we cloned a panel of DLBCL patient-derived mutations that all affected the CC domain of the CARMA1 scaffold (Figure 1a).9 Two ABC-derived (L244P and S243P) and two GCB-derived (F123I/K208M and L225LI) CARMA1 mutants were expressed in the GCB DLBCL cell line BJAB that lacks chronic BCR signaling and constitutive NF-κB activation. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.